LCDActive
Laser Ablation of the Prostate
L34090
Effective: March 27, 2025
Updated: December 31, 2025
Policy Summary
Laser ablation/enucleation of the prostate is covered for treatment of bladder neck obstruction due to benign prostatic hyperplasia when symptoms have persisted >=3 months and the AUA symptom score is >9. Urodynamics and post-void residual testing should be performed and documented when clinically indicated (e.g., suspected neurologic disease or prior failed prostate surgery), and procedures should be prescribed and personally supervised by a qualified physician; active urinary infection is a relative contraindication.
Coverage Criteria Preview
Key requirements from the full policy
"Laser prostatectomy is indicated for patients with bladder neck obstruction secondary to benign prostatic hyperplasia (BPH)."
Sign up to see full coverage criteria, indications, and limitations.